Reduction or de-escalation of dual antiplatelet therapy intensity or duration in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A mini-review

Reduction or de-escalation of dual antiplatelet therapy intensity or duration in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A mini-review

Current guidelines for patients with acute coronary syndrome (ACS) recommend dual antiplatelet therapy (DAPT) for 12 months. Since bleeding is the main Achilles' heel of DAPT, in recent years several randomized controlled trials have evaluated the safety and efficacy of de-escalation of DAPT wi...

Full description

Bibliographic Details
Main Authors: Mohamed Farag, Visvesh Jeyalan, Jose Luis Ferreiro, Young-Hoon Jeong, Tobias Geisler, Diana A. Gorog
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
acute coronary syndrome
PCI
antiplatelet therapy
P2Y12 inhibitor
de-escalation
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.1018649/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.1018649/full

Similar Items